How do you develop an investible opportunity that is commercially viable?

FACILITATED BY

Mike Lyne | Translational Research Management Lead | NIHR Biomedical Research Centre

PANELLISTS

Joe Healey | Chief Executive Officer and Co-Founder | NanoSyrinx

Jason Mellad | Chief Executive Officer | Start Codon

Stefanos Theoharis | Chief Business Officer | Kiji Therapeutics

Mustafa Munye | Vice President Operations | Complement Therapeutics

Catriona Crombie | Associate Director: Technology Transfer and Philanthropic Fund Manager | LifeArc

Discover how Process Analytical Technology can improve your ATMP manufacturing and scale up.

FACILITATED BY

Lee Dunham | Head of Collaboration | Cell and Gene Therapy Catapult

PANELLISTS

James Kusena | Vice President of Operations | MicrofluidX

Ian Anderson | Global Senior Principal Scientist, Global Biologics | Lonza

Andrea Cusack | CEO and Managing Director | leon-nanodrugs

Steven Binninger | Head of Process Science and Technology | autolomous

Andy Lewin | Chief Business Officer | Ascend Gene and Cell Therapies

How to present an investible opportunity, focusing on pitching, partnering and funding opportunities.

FACILITATED BY

Sam Goldsmith | Head of Commercialisation of Research and Investments | Cell and Gene Therapy Catapult

PANELLISTS

Jenny Laird | Vice President, Neuroscience Search & Evaluation | Eli Lilly and Company

Moin Saleem | Professor of Paediatric Renal Medicine | University of Bristol

Raj Mehta | Entrepreneur in Residence | Apple Tree Partners

Kerstin Papenfuss | Associate Director Therapeutics | Deep Science Ventures

Marcelo Bravo | Co Founder & Chief Executive Officer | OXVax

How to find the right partner to outsource your manufacturing and the considerations for setting up a productive partnership.

FACILITATED BY

Jesús Zurdo | Global Head Cell, Gene Therapy & Bioproduction | Horizon Discovery

PANELLISTS

Brian Mullan | Chief Technical Officer | Cell and Gene Therapies, Yposkesi

Michael Baker | Senior Director, Viral Gene Therapy | FUJIFILM Diosynth Biotechnologies

Rui Sousa | Co-founder and CEO | Stemmatters

James Fry | Partner and Head of Life Sciences | Mills & Reeve

What are VC Investors looking for at different stages of the life cycle? How is the current economic environment impacting Venture Capital?

FACILITATED BY

Nathan Sigworth | Co-founder and Chief Executive Officer | PharmaCCX

PANELLISTS

Freddie Dear | Head of Corporate Development & Portfolio Manager | Ascend Gene and Cell Therapies

Oliver Sexton | Investment Director | UKI2S

Dominic Schmidt | General Partner | Advent Life Sciences

Chris Baker | Investment Principal | LifeArc Ventures

Karolina Zapadka | Investor | Parkwalk Advisors

Understand when to keep manufacturing in-house and what you need to consider to make that a success e.g. what expertise and skills are required.

FACILITATED BY

Sharon Brownlow | Chief Business Officer | Cell & Gene Therapy Catapult

PANELLISTS

Kasia Averall | Head of Cluster Development | Cell and Gene Therapy Catapult

Angela Osborne | Chief Executive Officer | eXmoor pharma concepts

John Liddell | Chief Technologist | CPI Biologics

David Griffiths-Johnson | Head of Manufacturing | Office for Life Sciences

What do you need to consider to progress advanced therapies through the clinical phase of development to reach the marketplace?

FACILITATED BY

Flic Gabbay | Founding & Senior Partner | tranScrip

PANELLISTS

William Scott | Scientific Director, Transplant Regenerative Medicine | Newcastle University Medical School

Miguel Forte | Chief Executive Officer | Kiji Therapeutics

Agathe Guillot | Senior Regulatory Consultant | DLRC

Jimmy McBlane | Preclinical Assessor | MHRA

Raja Sharif | Founder and Chief Executive Officer | ATMPS Ltd

How has Industry 4.0 been adopted and where should the focus be? Our panel discusses digitalisation, sensors and automation, security and sustainability.

FACILITATED BY

Kwok Pang | COO and Co-Founder | Autolomous

PANELLISTS

Nick Stephens | Executive Chairman | The RSA Group

Antoine Espinet | Co Founder & Chief Executive Officer | MicrofluidX

Gaurav Venkataraman | Cofounder and Chief Executive Officer | Trisk Bio

Verity Nancollis | Associate Director, Biologics Development, Manufacturing & Control (BDM&C) | Pharmaron

Andreea Iftimia-Mander | Head of Biomatics | Biomatics

How do you plan ATMP Health Economics for early-stage R&D, ensuring commercial viability?

FACILITATED BY

Panos Kefalas | Director of the Access Strategy Group | Cell and Gene Therapy Catapult

PANELLISTS

Simon Chandler | Chief Executive Officer | Rinri Therapeutics

Kirsty Wydenbach | Head of Regulatory Strategy | Weatherden

Paul Catchpole | Value & Access Policy Director | Association of the British Pharmaceutical Industry (ABPI)

Steve Kappenthuler | Chief Business Officer and Co-founder | Muvon Therapeutics

Laura Beswick | Head of Health Economics and Market Access | Cell and Gene Therapy Catapult

Identifying the best targets, using AI, BioInformatics and ‘Omics’ approaches to improve biological understanding and predict efficacy and pharmacology for cell and gene therapies.

What should you consider when getting an advanced therapy ready for First in Human trials? Does it have the 5Rs: right target, right tissue, right safety, right patient and right commercial potential?

FACILITATED BY

Terri Gaskell | Chief Technical Officer | Rinri Therapeutics Ltd

PANELLISTS

Lee Coney | Head of Non-Clinical Safety | Cell and Gene Therapy Catapult

Mustafa Munye | Vice President Operations | Complement Therapeutics

Jimmy McBlane | Preclinical Assessor | MHRA

Neelam Panchal | Senior Commercialisation of Research Scientist | Cell and Gene Therapy Catapult

Fraser McBlane | Global Project Team Lead for Pharmacokinetic Sciences | Novartis